Pharmaxis Ltd (ASX:PXS)'s Gary Phillips tells Proactive the third dose cohort in the phase 1c clinical trial for the drug PXS‐5505 as a potential new treatment for the bone marrow cancer myelofibrosis is already fully recruited and dosing of all patients is expected to commence at participating sites in Australian and South Korean hospitals shortly. He also discusses the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBPA) conference in Miami, USA.
Pharmaxis updates on bone marrow cancer trial and talks potential of PXS-5505 in liver cancer
Quick facts: Pharmaxis Ltd
Price: 0.145 AUD
Market Cap: $65.79 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE